REG - RTW Venture Fund Ltd - Monthly Valuation Update

RTW Biotech OpportunitiesAnnouncement

17/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230417:nRSQ2984Wa&default-theme=true

RNS Number : 2984W  RTW Venture Fund Limited  17 April 2023

LEI: 549300Q7EXQQH6KF7Z84

17 April 2023

RTW Venture Fund Limited

Monthly Valuation Update

-5.2% NAV movement

RTW Venture Fund Limited (the "Company") announces that the unaudited net
asset value attributable to the ordinary shares of the Company at the close of
business on 31 March 2023 (the "NAV") was US$317.3 million, or US$1.49 per
ordinary share, a decrease of 5.2% from the previous month.

As of 31 March 2023, 26.7% of the total NAV was invested in privately held
core portfolio companies and 46.9% of the total NAV was invested in public
core portfolio companies, most of which were initiated as private investments.
29.1% was invested in other liquid public positions (which mirror holdings in
RTW Investments, LP private funds) in lieu of holding cash for future core
investments.

For Further Information:

 RTW Investments, LP                               +44 (0)20 7959 6361
 Woody Stileman, Managing Director

 Krisha McCune, Director, Client Service

 Buchanan                                          +44 (0)20 7466 5107
 Charles Ryland
 Henry Wilson
 George Beale

 Numis                                             +44 (0)20 7260 1000
 Freddie Barnfield
 Nathan Brown
 Euan Brown

 BofA Securities                                   +44 (0) 20 7628 1000
 Edward Peel
 Kieran Millar

 Elysium Fund Management Limited                   +44 (0) 14 8181 0100
 Joanna Duquemin Nicolle, Chief Executive Officer
 Sadie Morrison, Managing Director

 Morgan Stanley Fund Services USA LLC              +1 (914) 225 8885

 

 

 

Note:

 1.  The NAV is determined by the Company's investment manager, RTW Investments,
     LP, in accordance with the Company's accounting policies. Investments by the
     Company in privately-held companies ("Private Portfolio Companies") have been
     valued at fair market value, taking into account the valuation prepared by
     Alvarez & Marsal Valuation Services LLC and the nature, facts and
     circumstances of the Private Portfolio Companies. Investments by the Company
     in companies listed on a public stock exchange (the "Public Portfolio
     Companies") have each been valued by reference to their market capitalisation
     as at close of business on 31 March 2023. The Company applies a valuation
     discount to its investments in Public Portfolio Companies that are subject to
     post-IPO lock-up provisions.

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused
on identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Venture Fund invests in
companies developing next-generation therapies and technologies that can
significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading
healthcare-focused entrepreneurial investment firm with deep scientific
expertise and a strong track record of supporting companies developing
life-changing therapies.

Visit the RTW website at www.rtwfunds.com
(https://protect.mimecast-offshore.com/s/eY8OCgLEp4SlY4JEFN_vEF) for more
information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NAVFZLFFXZLFBBZ